### FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

			LACITATIOL	•
١,	abinaton	DC 1	20540	

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							

hours per response:

0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

													1							
1. Name and Address of Reporting Person*  Yale Catriona					2. Issuer Name and Ticker or Trading Symbol Akero Therapeutics, Inc. [ AKRO ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner							
															ctor cer (give title		Other (s			
(5:20)															w)		below)	specify		
(Last) (First) (Middle) 601 GATEWAY BOULEVARD						3. Date of Earliest Transaction (Month/Day/Year) 09/03/2024								Chief Development Officer						
		ULEVARD				09/03/2024								-						
SUITE 3	350																			
(Street)					- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
SOUTH	SAN													Line)  Form filed by One Reporting Person						
FRANCI	$\sim$	A	94080											Form filed by More than One Reporting						
,					-									Per				3		
(City)	(S	tate)	(Zip)																	
		Tab	le I - N	on-Deriv	/ative	Sec	uritie	es Ac	quired	l, Di	isposed o	of, or Be	eneficia	lly Own	ed					
1. Title of S	Security (Ins	tr. 3)		2. Transac	tion		Deeme		3.		4. Securitie				nount of			7. Nature		
• ' '				Date (Month/Da	y/Year)	ear) Execu if any (Monti		,	Transaction Code (Instr.		Disposed C	of (D) (Instr. 3, 4 and 8		Bene	Securities Beneficially		r Indirect	of Indirect Beneficial Ownership		
					// Year)			8)					Repo	Owned Following Reported			(Instr. 4)			
									Code	٧	Amount	(A) or (D)	Price		saction(s) : 3 and 4)					
Common	Stock			09/03/2	2024	024			<b>M</b> <sup>(1)</sup>		949	A	\$0.61	5	76,880		D			
Common Stock 09/03/20					2024				<b>S</b> <sup>(1)</sup>		949	D	\$27.614	(2)	75,931		D			
4 770 - 4	l.			(e.g., p	outs,		, war	rants	s, optio	ns,	posed of converti	ble sec	urities)				40	4 8 4		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transa Code ( 8)		tion of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an Amount of Securities Underlyin Derivative (Instr. 3 a	of s ig e Security	8. Price of Derivative Security (Instr. 5)	curity Securitie		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Benefic Owners ct (Instr. 4		
													Amount							
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Number of Shares							
Stock Option	\$0.615	09/03/2024			M <sup>(1)</sup>			949	(3)		09/26/2028	Common Stock	949	\$0	18,71	.5	D			

#### **Explanation of Responses:**

(Right to

Buy)

- 1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2024, previously adopted by the Reporting Person.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$27.50 to \$27.79, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 2.
- 3. The options are vested and currently exercisable.

/s/ Jonathan Young, Attorneyin-Fact

09/05/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.